Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Mayne Pharma Group Ltd (Mayne Pharma) is a pharmaceutical company that focuses on commercialising novel medicines and offers patients generic medicinal products. Its product portfolio includes aspirin tablets, doxycycline capsules, erythromycin capsules, metaraminol injection, oxycodone tablets, fluorouracil and salicylic‑acid solution, morphine sulfate capsules, neem‑extract solutions, magnesium sulfate and glycerol gel, fosfomycin trometamol granules, and pain‑relief creams, among others. Mayne Pharma also provides contract development and manufacturing services. The company markets its products under the brands ACTIKERALL, ASTRIX, DORYX, KAPANOL, LICENER, LOZANOC, MAGNOPLASM, and SPLINTEX. It operates in Australia, the UK, the US, and Ireland. Mayne Pharma is headquartered in Adelaide, South Australia, Australia.
Headquarters
Australia
Address
1538 Main North Road, Salisbury South, Adelaide, South Australia, 5106
Website
www.maynepharma.com
Telephone
61 8 82092666
No of Employees
450
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MYX (ASX)
Revenue (2024)
$273.0M
4.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
46.1%
(2024 vs 2023)
Market Cap*
$160.1M
Net Profit Margin (2024)
XYZ
48.4%
(2024 vs 2023)
* As of and is in US$
Mayne Pharma Group Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Aspirin Tablets | Contract Development and Manufacturing Services | ACTIKERALL |
| Doxycycline Capsules | ASTRIX | |
| Erythromycin Capsules | DORYX | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Others | In December, the company announced to terminate its agreement to sell all its shares to Cosette Pharmaceuticals, Inc. |
| 2025 | Corporate Changes/Expansions | In December, the company opened the expanded manufacturing facility in Salisbury, South Australia. |
| 2025 | Contracts/Agreements | In April, the company's subsidiary entered into a US$16 million agreement with Sol-Gel Technologies for the US rights to EPSOLAY and TWYNEO. |
Competitor Comparison
| Key Parameters | Mayne Pharma Group Ltd | IDT Australia Ltd | Botanix Pharmaceuticals Ltd | Biocina Pty Ltd | Southern RNA Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Adelaide | Melbourne | Perth | Thebarton | Gold Coast |
| State/Province | South Australia | Victoria | Western Australia | South Australia | Queensland |
| No. of Employees | 450 | 156 | 50 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Aaron Gray | Chief Executive Officer | Senior Management | 2026 | - |
| Frank Casty | Executive Vice President; Chief Medical Officer; Global Head - Research and Development | Senior Management | - | - |
| Grant Swart | Vice President - Australia; General Manager | Senior Management | 2023 | - |
| Kimberly Parker | Executive Vice President; General Counsel | Senior Management | 2022 | - |
| Erinn Nathaniel | Global Head - People and Culture; Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer